After Hours Top Loser 23 Mar 2026: EVE.SW EvoNext Holdings S.A. (SIX) down 9.23% to CHF0.826, watch cash metrics

EVE.SW stock led Swiss small-cap losses after hours on 23 Mar 2026, slipping -9.23% to CHF0.826 on low volume. Traders reacted to no new guidance and stretched short-term momentum, pushing the biotech name below its 50-day average. The after-hours move highlights liquidity limits for EvoNext Holdings S.A. on the SIX and raises near-term risk for holders ahead of the August earnings date.

After-hours price action and context for EVE.SW stock

EVE.SW stock closed the regular session at CHF0.91 and traded CHF0.826 in after-hours trade, a -9.23% drop on volume 1,465 shares. This move leaves the share price under the 50-day average of CHF0.86 and well below the 200-day average of CHF0.94. The low liquidity versus average volume 8,028 increases slippage risk for large orders.

Fundamental snapshot: valuation and balance-sheet signals

EvoNext Holdings S.A. reports EPS -0.12 and a negative P/E of -6.83, reflecting losses. The company shows cash per share CHF0.87 and book value per share CHF0.86, giving a price-to-book near 0.95. Market cap stands at CHF5,913,473.00, so balance-sheet strength is relative but limited by small scale.

Technical read: momentum, volatility and trend indicators for EVE.SW stock

Momentum turned negative with RSI 44.53 and MACD below signal. ADX at 42.08 signals a strong trend, currently downward. Bollinger Bands place the lower band at CHF0.81, near the after-hours price, increasing probability of short-term volatility. CCI and MFI readings show oversold conditions that can produce rapid bounces on news.

Meyka AI grade, forecast and price targets for EVE.SW stock

Meyka AI rates EVE.SW with a score out of 100: 67.93 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparison, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of CHF1.46, implying +77.29% upside from CHF0.826. Short-term model guidance is lower, with a quarterly target of CHF0.54. Forecasts are model-based projections and not guarantees.

Sector context and catalysts for EVE.SW stock

EvoNext sits in Healthcare and Biotechnology, where the Swiss sector average P/E is 26.77. EVE.SW’s negative P/E and small market cap expose it to sector rotations and funding risk. Key catalysts include trial updates, licensing news, and the next earnings announcement on 2026-08-20. Any positive clinical or commercial milestone could re-rate the stock quickly due to low free float.

Risks, trading checklist and quick strategy for EVE.SW stock

Primary risks include continued operating losses, low trading volume, and dilution if capital raises are needed. For active traders, watch volume spikes above 8,000 and the CHF0.81–CHF0.90 band for breakout or breakdown confirmation. For investors, validate cash runway and milestone timelines before adding exposure. Use tight size limits because market cap is CHF5.91m and liquidity is constrained.

Final Thoughts

EVE.SW stock is the top after-hours loser on 23 Mar 2026, falling -9.23% to CHF0.826 on thin volume. Fundamentals show a small balance sheet with cash per share CHF0.87 and book value near CHF0.86, yet the name posts negative earnings and a negative P/E. Technicals signal a strong downtrend but oversold momentum readings can produce volatile rebounds. Meyka AI’s forecast model projects a yearly target of CHF1.46, implying +77.29% from the current price, while the quarterly target sits at CHF0.54, showing near-term downside risk. Our Meyka grade is 67.93 (B, HOLD), which weighs sector comparison, growth metrics, and analyst signals. Given the small market cap (CHF5,913,473.00) and low liquidity, traders should size positions conservatively and monitor catalysts such as licensing news or the 20 Aug earnings report. Forecasts are model-based projections and not guarantees. For real-time alerts and further EVE.SW stock updates, Meyka AI provides live data and screening tools to track momentum and volume shifts.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.